Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Investment analysts at Cantor Fitzgerald raised their FY2024 earnings estimates for Capricor Therapeutics in a note issued to investors on Wednesday, September 25th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings of ($1.28) per share for the year, up from their prior forecast of ($1.31). Cantor Fitzgerald has a "Overweight" rating and a $8.00 price objective on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.14) per share.
Several other research analysts also recently issued reports on the stock. Maxim Group upped their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Capricor Therapeutics in a research report on Tuesday. Finally, Oppenheimer reissued an "outperform" rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to data from MarketBeat, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $22.60.
View Our Latest Stock Report on CAPR
Capricor Therapeutics Price Performance
Shares of CAPR stock traded down $0.04 during trading hours on Friday, hitting $9.95. 2,546,641 shares of the company's stock were exchanged, compared to its average volume of 779,550. Capricor Therapeutics has a 52 week low of $2.68 and a 52 week high of $12.87. The stock has a market cap of $318.19 million, a price-to-earnings ratio of -11.44 and a beta of 3.92. The stock's 50-day moving average is $4.80 and its 200-day moving average is $5.31.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The business had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million.
Insider Activity at Capricor Therapeutics
In related news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm's stock in a transaction dated Friday, September 20th. The stock was bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the transaction, the insider now owns 7,090,351 shares of the company's stock, valued at $38,004,281.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 12.00% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the company. Marshall Wace LLP acquired a new position in Capricor Therapeutics in the second quarter valued at about $426,000. Renaissance Technologies LLC grew its position in shares of Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after purchasing an additional 84,350 shares during the period. Main Street Financial Solutions LLC increased its stake in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock worth $131,000 after purchasing an additional 7,500 shares in the last quarter. Rhumbline Advisers acquired a new stake in Capricor Therapeutics during the 2nd quarter worth approximately $147,000. Finally, Bank of New York Mellon Corp raised its holdings in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after buying an additional 9,040 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
